Dynamic Contrast-Enhanced MRI of Malignant Pleural Mesothelioma

A Feasibility Study of Noninvasive Assessment, Therapeutic Follow-up, and Possible Predictor of Improved Outcome

      Study objective

      Dynamic contrast-enhanced MRI (DCE-MRI) followed by pharmacokinetic analysis has been successfully used in a variety of solid tumors. The aims of this study were to evaluate the feasibility of DCE-MRI in malignant pleural mesothelioma (MPM), to differentiate benign from pathologic tissue and compare pharmacokinetic with clinical parameters and survival in order to map out its microcirculation; and to compare pharmacokinetic with clinical parameter and survival in order to improve our understanding of the in vivo biology of this malignancy.


      Nineteen patients with a diagnosis of MPM who were scheduled to receive chemotherapy with gemcitabine were enrolled in the study. DCE-MRI was performed before treatment (n = 19) and after the third cycle (n = 12) and sixth cycle (n = 7) of chemotherapy. An established pharmacokinetic two-compartment model was used to analyze DCE-MRI. Tumor regions were characterized by the pharmacokinetic parameters amplitude (Amp), redistribution rate constant (kep), and elimination rate constant (kel). Kinetic parameters of tumor tissue and normal tissue were compared using the Student t test. Patients were classified as clinical responders or nonresponders according to clinical outcome, and these groups were compared with the pharmacokinetic parameters derived from DCE-MRI.


      Normal and tumor tissue could be distinguished by the pharmacokinetic parameters Amp and kel (p ≤ 0.001). Clinical responders had a median kep value within the tumor of 2.6 min, while nonresponders showed a higher value (3.6 min), which coincided with longer survival (780 days vs 460 days).


      DCE-MRI can be used in patients with MPM to assess tumor microvascular properties and to demonstrate tumor heterogeneity for therapy monitoring. High pretherapeutic values of kep within the tumor correlated with a poor overall response to therapy.

      Key words


      Amp (amplitude), DCE-MRI (dynamic contrast-enhanced MRI), FDG (fluorodeoxyglucose), kel (elimination rate constant), kep (redistribution rate constant), MPM (malignant pleural mesothelioma), PET (positron emission tomography), ROI (region of interest), VEGF (vascular endothelial growth factor)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Antman KH
        • Li FP
        • Pass HI
        • et al.
        Benign and malignant mesothelioma.
        Cancer: principles and practice of oncology. Lippincott, Philadelphia, PA1993: 1489-1508 (De Vita, VT, Jr, Hellman, S Rosenberg, SA eds 4th ed.)
        • Chahinian AP
        Malignant mesothelioma.
        Cancer medicine. Lea & Febiger, Philadelphia, PA1993: 1337-1354 (Holland, JF Frei, E Bast, RC et al eds 3rd ed.)
        • Ruffie P
        • Feld R
        • Minkin S
        • et al.
        Current approach to malignant mesothelioma of the pleura.
        Chest. 1995; 107: 332S-344S
        • Stewart DJ
        • Edwards JG
        • Smythe WR
        • et al.
        Malignant pleural mesothelioma: an update.
        Int J Occup Environ Health. 2004; 10: 26-39
        • Steinert DJ
        • Santos Dellea MM
        • Burger C
        • et al.
        Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
        Lung Cancer. 2005; 49: S33-S35
        • Rusch VW
        • Godwin JD
        • Shuman WP
        • et al.
        The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 1988; 96: 171-177
        • Benard F
        • Sterman D
        • Smith RJ
        • et al.
        Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
        Chest. 1998; 114: 713-722
        • Niethammer AG
        • Xiang R
        • Becker JC
        • et al.
        A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.
        Nat Med. 2002; 8: 1369-1375
        • Haberkorn U
        Positron emission tomography in the diagnosis of mesothelioma.
        Lung Cancer. 2004; 45: S73-S76
        • Schneider DB
        • Clary-Macy C
        • Challa S
        • et al.
        Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 2000; 129: 128-133
        • Jeswani T
        • Padhani AR
        Imaging tumor angiogenesis.
        Cancer Imaging. 2005; 5: 131-138
        • Lardinois D
        • Weder W
        • Hany TF
        • et al.
        Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
        N Engl J Med. 2003; 348: 2500-2507
        • Choyke PL
        • Dwyer AJ
        • Knopp MV
        Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
        J Magn Reson Imaging. 2003; 17: 509-520
        • Hawighorst H
        • Knopp MV
        • Debus J
        • et al.
        Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results.
        J Magn Reson Imaging. 1998; 8: 783-788
        • Knopp MV
        • Weiss E
        • Sinn HP
        • et al.
        Pathophysiologic basis of contrast enhancement in breast tumors.
        J Magn Reson Imaging. 1999; 10: 260-266
        • Hall GH
        • Atkin SL
        • Turnbull LW
        Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries.
        J Reprod Med. 2002; 47: 107-114
        • Kroep JR
        • Peters GJ
        • van Moorsel CJ
        • et al.
        Gemcitabine-cisplatin: a schedule finding study.
        Ann Oncol. 1999; 10: 1503-1510
        • Kayser K
        • Bohm G
        • Blum S
        • et al.
        Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
        J Pathol. 2001; 193: 175-180
        • Butchart EG
        • Ashcroft T
        • Barnsley WC
        • et al.
        Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients.
        Thorax. 1976; 31: 15-24
        • Brix G
        • Semmler W
        • Port R
        • et al.
        Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.
        J Comput Assist Tomogr. 1991; 15: 621-628
        • Hoffmann U
        • Brix G
        • Knopp MV
        • et al.
        Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
        Magn Reson Med. 1995; 33: 506-514
        • Peto J
        • Hodgson JT
        • Matthews FE
        • et al.
        Continuing increase in mesothelioma mortality in Britain.
        Lancet. 1995; 345: 535-539
        • Boutin C
        • Rey F
        • Gouvernet J
        Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987.
        Bull Acad Natl Med. 1992; 176: 105-114
        • Butchart EG
        Surgery of mesothelioma of the pleura.
        Thoracic oncology. W. B. Saunders, Philadelphia, PA1989: 566-583 (Roth, JA Ruckdeschel, JC Weinseinberger, TH eds)
        • Rusch VW
        • Piantadosi S
        • Holmes EC
        The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group trial.
        J Thorac Cardiovasc Surg. 1991; 102: 1-9
        • Mattson K
        • Holsti LR
        • Tammilehto L
        • et al.
        Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
        Int J Radiat Oncol Biol Phys. 1992; 24: 643-650
        • Gordon Jr, W
        • Antman KH
        • Greenberger JS
        • et al.
        Radiation therapy in the management of patients with mesothelioma.
        Int J Radiat Oncol Biol Phys. 1982; 8: 19-25
        • Davis SR
        • Tan L
        • Ball DL
        Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
        Australas Radiol. 1994; 38: 212-214
        • Ong ST
        • Vogelzang NJ
        Chemotherapy in malignant pleural mesothelioma: a review.
        J Clin Oncol. 1996; 14: 1007-1017
        • Hasturk S
        • Tastepe I
        • Unlu M
        • et al.
        Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
        J Chemother. 1996; 8: 159-164
        • Marom EM
        • Erasmus JJ
        • Pass HI
        • et al.
        The role of imaging in malignant pleural mesothelioma.
        Semin Oncol. 2002; 29: 26-35
        • Knopp MV
        • Bischoff H
        • Lorenz WJ
        • et al.
        PET imaging of lung tumours and mediastinal lymphoma.
        Nucl Med Biol. 1994; 21: 749-757
        • Gerbaudo VH
        • Britz-Cunningham S
        • Sugarbaker DJ
        • et al.
        Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma.
        Thorax. 2003; 58: 1077-1082
        • Detterbeck FC
        • Vansteenkiste JF
        • Morris DE
        • et al.
        Seeking a home for a PET, part 3: emerging applications of positron emission tomography imaging in the management of patients with lung cancer.
        Chest. 2004; 126: 1656-1666
        • Folkman J
        Tumor angiogenesis: therapeutic implications.
        N Engl J Med. 1976; 285: 1182-1186
        • Mattern J
        • Koomagi R
        • Volm M
        Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas.
        Int J Oncol. 1995; 6: 1059
        • Samoto K
        • Ikezaki K
        • Ono M
        • et al.
        Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.
        Cancer Res. 1995; 55: 1189-1193
        • Takahashi Y
        • Kitadai Y
        • Bucana CD
        • et al.
        Expression of vascular endothelial growth factor and its receptor KDR, correlation with vascularity, metastasis, and proliferation of human colon cancer.
        Cancer Res. 1995; 55: 3964-3968
        • Weidner N
        • Semple JP
        • Welch WR
        • et al.
        Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma.
        N Engl J Med. 1991; 324: 1-8
        • Macchiarini P
        • Fontanini G
        • Hardin MJ
        • et al.
        Relation of neovascularisation to metastasis on non-small cell lung cancer.
        Lancet. 1991; 340: 145-146
        • Toi M
        • Hoshina S
        • Takayagani T
        Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.
        Jpn J Cancer Res. 1994; 85: 1045
        • Chodak GW
        • Haudenschild C
        • Gittes RF
        Angiogenic activity as a marker of neoplasia and pre-neoplasia in lesions of the human bladder.
        Ann Surg. 1980; 192: 762-771
        • Kumar-Singh S
        • Vermeulen PB
        • Weyler J
        • et al.
        Evaluation of tumour angiogenesis as a prognostic factor in malignant mesothelioma.
        J Pathol. 1997; 182: 211-216
        • Ohta Y
        • Shridhar V
        • Bright RK
        • et al.
        VEGF and VEGF type C play an important role in angiogenesis in human malignant mesothelioma tumours.
        Br J Cancer. 1999; 81: 54-61
        • Knopp MV
        • Weiss E
        • Sinn HP
        • et al.
        Pathophysiologic basis of contrast enhancement in breast tumors.
        J Magn Reson Imaging. 1999; 10: 260-266
        • Kiessling F
        • Boese J
        • Corvinus C
        • et al.
        Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization an treatment monitoring?.
        Eur Radiol. 2004; 14: 1226-1233